Effect of evolocumab or ezetimibe added to moderate- Or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial

JAMA

Volumn 311, Issue 18, 2014, Pages 1870-1882

  Robinson, Jennifer G ^a,b   Nedergaard, Bettina S ^c   Rogers, William J ^d   Fialkow, Jonathan ^e   Neutel, Joel M ^f   Ramstad, David ^g   Somaratne, Ransi ^h   Legg, Jason C ^h   Nelson, Patric ^h   Scott, Rob ^h   Wasserman, Scott M ^h   Weiss, Robert ⁱ   Hamilton, A ^j   Lehman, R ^j   Proietto, J ^j   Simons, L ^j   Bous, J P ^j   Cornelli, K ^j   De Munck, L ^j   Vantroyen, ^j   Vermeersch, L ^j   Vileyn, G ^j   Akhras, R ^j   Cha, J ^j   Chehayeb, R ^j   Chilvers, M ^j   Collette, R ^j   Dowell, A ^j   Dzongowski, P ^j   Gupta, A ^j   Halperin, F ^j   Hart, R ^j   Heaton, K ^j   Henein, S ^j   Kanani, S ^j   Kornder, J ^j   Lamy, A ^j   OMahony, M ^j   Pandey, A ^j   Sabe Affaki, G ^j   St Maurice, F ^j   Adamkova, V ^j   Cermak, O ^j   Ceska, R ^j   Frana, P ^j   Hala, T ^j   Kellnerova, I ^j   Machkova, M ^j   Petrzelkova, J ^j   Pojsl, S ^j   Stankova, V ^j   Vaclavik, J ^j   Zemanek, J ^j   Krogsaa, A ^j   Wermuth, S ^j   Clavel, S ^j   Cohen, A A ^j   Davy, J M ^j   Joubert, M ^j   Mansourati, J ^j   Probst, V ^j   Verges, B ^j   Degtyareva, E ^j   Forster A ^j   Horacek, T ^j   Kasperk, C ^j   Kohler, E ^j   Laufs, U ^j   Meissner, G ^j   Schenkenberger, I ^j   Stoessel, J ^j   Trenk, D ^j   Winkler, K ^j   Lau, E M ^j   Yeung, C Y ^j   Bajnok, L ^j   Bod, E ^j   Harcsa, E ^j   Lippai, J ^j   Mohacsi, A ^j   Palinkas, A ^j   Poor, F ^j   Szakal, I ^j   Sziegl, Z ^j   Borghi, C ^j   Bucci, M ^j   Cattin, L ^j   Iannuzzi, A ^j   Miccoli, R ^j   Passaro, Angelina ^j   Pintus, P ^j   Pirro, M ^j   Sirtori, C ^j   Zambon, S ^j   De Graaf, J ^j   Donders, S ^j   Imholz, B ^j   Klessens Godfroy, F ^j   Kooy, A ^j   Stroes, E ^j   Van Leendert, R ^j   Viergever, P ^j   Helder, D ^j   Vincent, H ^j   Barbarash, O ^j   Chumakova, G ^j   Demchenko, E ^j   Kotelnikov, M ^j   Litvin, A ^j   Lukyanov, Y ^j   Shvarts, Y ^j   Susekov, A ^j   Treshkur, T ^j   Yakhontova, P ^j   Gimilio, J F ^j   Gimeno, E J ^j   Raya, P M ^j   Nunez Cortes J M ^j   Prieto, J M ^j   Sala, X P ^j   Ros, E ^j   Borgencrantz, B ^j   Bosson, P ^j   Curiac, D ^j   Dahlen G ^j   Delavaran, C ^j   Lindholm, C J ^j   Burnier, M ^j   Eberli, F ^j   Gallino, A ^j   Mach, F ^j   Rickli, H ^j   Widmer, F ^j   Abdulhakim, E E ^j   Adler, L ^j   Blagden, M ^j   D'Costa, R ^j   Falk, R ^j   Fisher, M ^j   Hassanin, H ^j   Horvathova, V ^j   Kerrane, J ^j   Mackay, J ^j   McCormack, T ^j   McKinnon, C ^j   Oyesile, B ^j   Pavel Knox, I ^j   Soran, H ^j   Thomas, H ^j   Abraham, W ^j   Aronoff, S ^j   Atassi, K ^j   Awasty, V ^j   Bailey, K ^j   Baron, S ^j   Bear, R ^j   Bertolet, B ^j   Bhagwat, R ^j   Coburn, N ^j   Connery, L ^j   Dauber, I ^j   Davis, M ^j   Diederich, C ^j   Eaton, G ^j   Fishbein, G ^j   French, W ^j   Friedlander, I ^j   Fuchs Ertman, D ^j   Ginsberg, D ^j   Hagan, M ^j   Hage Korban, E ^j   Halpern, S ^j   Henderson, D ^j   Houser, P ^j   Ibrahim, H ^j   Jennings, W ^j   Kivitz, A ^j   Kozlowski, L ^j   Loh, I ^j   Malone, M ^j   McConnehey, B ^j   McCullum, K ^j   Miller, M ^j   Napoli, M ^j   Purdy, D ^j   Qureshi, M ^j   Raoof, T ^j   Reichman, A ^j   Rich, K ^j   Salazar, J ^j   Shaoulian, E ^j   Stringer, J ^j   Tarleton, G ^j   Throne, M ^j   Webb, C ^j   Wiseman, A ^j   more..

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^f Orange County Research Center   (United States)

^g Hampton Roads Center for Clinical Research   (United States)

^h AMGEN INC   (United States)

ⁱ Maine Research Associates   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DISTURBANCE; BACKACHE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISORIENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LIMB PAIN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84900303213     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.4030     Document Type: Article

References (24)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet. 2010;376(9753):1670-1681.
2. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online November 7, 2013]. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.11.002.
3. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151-167.
4. Grundy SM; Expert Dyslipidemia Panel. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7(6):561-565.
5. Perk J, De Backer G, Gohlke H, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-1701.
6. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435. (Pubitemid 40471450)
7. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA. 2005;294(19):2437-2445. (Pubitemid 41627921)
8. Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population. Atherosclerosis. 2012;224(1):150-153.
9. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106(24):9820-9825.
10. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL). Lancet. 2012;380(9858):1995-2006.
11. Giugliano RP, Desai NR, Kohli P, et al LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57). Lancet. 2012;380(9858):2007-2017.
12. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. JAMA. 2012;308(23):2497-2506.
13. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia. Circulation. 2012;126(20):2408-2417.
14. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia. Circulation. 2014;129(2):234-243.
15. Robinson JG, Rogers WJ, Nedergaard BS, et al. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy [published online January 30, 2014]. Clin Cardiol. doi:10.1002/clc.22252.
16. Hochberg T. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
17. Weins BL. A fixed sequence bonferroni procedure for testing multiple endpoints. Pharm Stat. 2003;2:211-215.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
19. Civeira Oterman F, Raal FJ, Stein EA, et al. Statin therapy is a major determinant of PCSK9 plasma concentration: data from four clinical trials with AMG 145 [published online August 31, 2013]. Eur Heart J. doi:10.1093/eurheartj/ eht307.P681.
20. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826-832.
21. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/NCT01764633. Accessed August 29, 2013.
22. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-1504. (Pubitemid 38477774)
23. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. J Am Coll Cardiol. 2011;57(16):1666-1675.
24. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol. 2006;98(10):1405-1408. (Pubitemid 44666653)